ReviewInternational journal of molecular sciences2023
Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Phytochemical Analysis Using LC-MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights.Chemistry & biodiversity · 2026Article
- Zein-Pectin Nanoparticles for Luteolin Delivery: Physicochemical Characterization, Antioxidant Activity, and Simulated Gastrointestinal Behavior.Journal of food science · 2026Article
- Exploration of network-based, machine learning, MD simulations, and MM/GBSA approaches revealed luteolin from Gynura procumbens as key inhibitor of MMP9 in NSCLC.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Luteolin in osteoarticular diseases: a review of preclinical studies and translational perspectives.Inflammopharmacology · 2026Review
- Myricetin Inhibits Osteosarcoma Cell Viability and Modulates EMT-Related Genes Associated with thePharmaceuticals (Basel, Switzerland) · 2026Article
- Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors.Discover oncology · 2026Review
- Luteolin-7-O-rutinoside alleviates rheumatoid arthritis through downregulation of the PI3K/AKT/NF-κB and cell cycle signaling pathways.Frontiers in pharmacology · 2026Article
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications.Cancer pathogenesis and therapy · 2025Review
- Bioinspired 3D hydrogel scaffold to mimic tumor microenvironment for investigating into the anoikis resistance mechanisms in colorectal cancer.Materials today. Bio · 2025Article
- Application of PVA hydrogel loaded with luteolin nanoparticles in anti EMT treatment after GBM.Materials today. Bio · 2025Article
- Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.International journal of molecular sciences · 2025Review
- Phytochemical Profile and Anticancer Potential ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Inhibitory effect of luteolin on the metabolism of vandetanibFrontiers in pharmacology · 2025Article
- Accurate prediction of drug-target interactions in Chinese and western medicine by the CWI-DTI model.Scientific reports · 2024Article
- Quantitative Analysis of Flavonoids in Fruiting Bodies ofMolecules (Basel, Switzerland) · 2023Article
- Analysis of some flavonoids for inhibitory mechanism against cancer target phosphatidylinositol 3-kinase (PI3K) using computational tool.Frontiers in pharmacology · 2023Article
- The role and mechanism of TCM in the prevention and treatment of infectious diseases.Frontiers in microbiology · 2023Review
- Phytochemicals in Cancer Chemoprevention: Preclinical and Clinical Studies.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin (3',4',5,7-tetrahydroxyflavone), a member of the flavonoid family derived from plants and fruits, shows a wide range of biomedical applications. In fact, due to its anti-inflammatory, antioxidant and immunomodulatory activities, Asian medicine has been using luteolin for centuries to treat several human diseases, including arthritis, rheumatism, hypertension, neurodegenerative disorders and various infections. Of note, luteolin displays many anti-cancer/anti-metastatic properties. Thus, the purpose of this review consists in highlighting the relevant mechanisms by which luteolin inhibits tumor progression in metastasis, i.e., affecting epithelial-mesenchymal transition (EMT), repressing angiogenesis and lysis of extracellular matrix (ECM), as well as inducing apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.